Idramantone (Kemantane)
(Synonyms: 伊决孟酮; Kemantane; 5-Hydroxy-2-adamantanone) 目录号 : GC30998
Idramantone (Kemantane, 5-Hydroxy-2-adamantanone) is an immune agonist.
Cas No.:20098-14-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Idramantone (Kemantane, 5-Hydroxy-2-adamantanone) is an immune agonist.
| Cas No. | 20098-14-0 | SDF | |
| 别名 | 伊决孟酮; Kemantane; 5-Hydroxy-2-adamantanone | ||
| Canonical SMILES | O=C1C(C2)CC3CC2(O)CC1C3 | ||
| 分子式 | C10H14O2 | 分子量 | 166.22 |
| 溶解度 | Water : 20 mg/mL (120.32 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.0161 mL | 30.0806 mL | 60.1612 mL |
| 5 mM | 1.2032 mL | 6.0161 mL | 12.0322 mL |
| 10 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Kemantane pharmacokinetics in rats]
Pharmacokinetics of novel immunostimulating drug kamantane was studied by using gas-liquid chromatography in experiments on rats. It was found that kemantane biotransformed rapidly after oral administration with the forming of active metabolite. Kemantane and its metabolites are distributed rapidly from the blood to organs. The drug is eliminated from the organism of rats as metabolite.
[The clinical pharmacokinetics of kemantane]
The pharmacokinetics of a new Soviet-made immunostimulant kemantane, a derivative of adamantine, was studied by gas-liquid chromatography in patients with bronchial pathology. It was found that in the blood of the patients kemantane was not practically detected due to a pronounced effect of the "first pass" through the liver. Kemantane kinetics was evaluated by the kinetics of its major active metabolite. On the basis of the performed studies the scheme of using kemantane in the patients with decreased immunity was recommended.
[Interspecific differences in kemantan pharmacokinetics]
The pharmacokinetics of the new immunostimulant kemantane, adamantane derivative, used in two species of animals (rats and rabbits) and man was studied. There were significant differences in the pharmacokinetics of kemantane and its active metabolite--adamantane-1,4-diol between the species.
[The mitostatic and lymphotoxic action of kemantane and its effect on B-suppressors]
The in vivo study of the influence of Kemantan on the growth of endogenous colonies in the spleen of sublethally (6 Gy) irradiated (CBA x C57BL/6J) F1 mice (mitostatic action) and on the capacity of transplanted lymphocytes of CBA mice for suppressing their multiplication (lymphotoxic action) was carried out. Besides the capacity of Kemantan for affecting the induction, formation and functioning of B-suppressors of antibody formation was studied. As revealed in this study, Kemantan in doses of 0.2-200 mg/kg did not produce a mitostatic and lymphotoxic effect and had no influence on the realization of the suppressing action of mature B-suppressors. In doses of 20 and 200 mr/kg Kemantan, injected to donors at the phase of the induction and accumulation of B-suppressors, abolished their formation.
[The effect of kemantane on T-helpers and T-suppressors]
The study of Kemantan on functionally alternative humoral immunity regulator cells: T-helpers and antigen-specific T-suppressors, including their induction, accumulation and functioning, was studied. Kemantan in doses of 0.2-200 mg/kg, introduced to the donors of T-helpers 2 days before they were taken, stimulated their activity 1.5- to 2-fold (with p less than 0.05). Kemantan had no influence on the functional activity of T-suppressors, as well as on their induction and accumulation.